We are pleased to announce that Professor Hans Clevers will give the opening keynote lecture, and Professor Donald Ingber will give the closing keynote lecture. The programme will feature a session dedicated to immunotherapy for the first time, with Professor Ronald Germain giving the immunotherapy keynote lecture.
Who should attend? The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad and detailed overview of the most recent advances in the study of tumour biology, bioengineering and biochemistry, drug target validation, compound and antibody screening, toxicology, and patient-tumour profiling.
Who should attend? The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad and detailed overview of the most recent advances in the study of tumour biology, bioengineering and biochemistry, drug target validation, compound and antibody screening, toxicology, and patient-tumour profiling.
